The landscape for prostate-cancer biomarkers is getting crowded; OPK (a company I don’t especially like) is joining the fray: http://finance.yahoo.com/news/OPKO-Health-Acquires-Next-bw-3646483412.html?x=0 The unmet need is large, but I have no idea as to which companies will come out winners in this endeavor.